EPIVAX THERAPEUTICS, INC.
Science Without Fear
EpiVax Therapeutics ('EVT'), an emerging biotechnology startup founded in 2017, employs a world-leading technology, developed over 22 years by EpiVax, to design vaccines that aim to activate the body’s T cells to cure or prevent disease in the host. EVT’s pipeline includes a COVID-19 vaccine and a personalized bladder cancer vaccine.
For more information regarding EVT's cancer immunotherapies, please click here.